Her signaling in pancreatic cancer

Bibliography

• BURRIS HA 3rd, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
   PubMed Web of Science ®Google Scholar
• ODAKA M, KOHDA D, LAX I, SCHLESSINGER J: Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. J. Biochem. (1997) 122:116-121.
   PubMed Web of Science ®Google Scholar
• GARRETT TPJ, MCKERN NM, LOU M et al.: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 110:763-773.
   PubMed Web of Science ®Google Scholar
• OSIGO M, ISHITANI R, NUREKI O et al.: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domain. Cell (2002) 110:775-787.
   PubMed Web of Science ®Google Scholar
• WHITSON KB, WHITSON SR, RED-BREWER ML et al.: Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochem. (2005) 44:14920-14931.
   PubMed Web of Science ®Google Scholar
• GRAUS-PORTA D, BEERLI RR, DALY JM, HYNES NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. (1997) 16:1647-1655.
   PubMed Web of Science ®Google Scholar
• LO H-W, XIA W, WEI Y et al.: Novel prognostic value of nuclear EGF receptor in breast cancer. Cancer Res. (2005b) 65:338-348.
   PubMed Web of Science ®Google Scholar
• PSYRRI A, YU Z, WEINBERGER PM et al.: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin. Cancer Res. (2005) 11:5856-5862.
   PubMed Web of Science ®Google Scholar
• LO HW, HUNG MC: Nuclear EGFR signaling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Cancer (2006) 94:184-188.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, BANERJEE S, WANG Z et al.: Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor κB in pancreatic cancer. Cancer Res. (2006) 66:1025-1032.
   PubMed Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Proc. Am. Soc. Clin. Oncol. (2005) 24:Abstract 1.
   Google Scholar
• GRUBBS SS, GRUSENMEYER PA, PETRELLI NJ, GRALLA RJ: Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? J. Clin. Oncol. (2006) 24(18S):313s:Abstract 6048.
   Google Scholar
• XIONG HQ, ROSENBERG A, LoBUGLIO A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. (2004) 22:2610-2616.
   PubMed Web of Science ®Google Scholar
• CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23:1803-1810.
   PubMed Web of Science ®Google Scholar
• BLEICKARDT E, ARGIRIS A, RICH R et al.: Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol. Ther. (2002) 1:646-651.
   PubMed Web of Science ®Google Scholar
• BURTNESS B, THOMAS L, SIPPLES R et al.: Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Ca. J. (2007) (In Press).
   Google Scholar
• GRAEVEN U, KREMER B, SUDHOFF T et al.: Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer (2006) 94:1293-1299.
   PubMed Web of Science ®Google Scholar
• WIRTH LJ, HADDAD RI, LINDEMAN NI et al.: Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23:6976-6381.
   PubMed Web of Science ®Google Scholar
• JIMENO A, RUBIO-VIQUIERA B, AMADOR ML et al.: Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. (2005) 65:3003-3010.
   PubMed Web of Science ®Google Scholar
• VILORIA-PETIT A, CROMBET T, JOTHY S et al.: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo:a role for altered tumor angiogenesis. Cancer Res. (2001) 61:5090-5101.
   PubMed Web of Science ®Google Scholar
• YOKOI K, SASAKI T, BUCANA CD et al.: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. (2005) 65:10371-10380.
   PubMed Web of Science ®Google Scholar
• KINDLER HL, BYLOW KA, HOCHSTER HS et al.: A randomized Phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis. J. Clin. Oncol. (2006) 24(18S):Abstract 4040.
   Google Scholar
• KINDLER HL, NIEDZWIECKI D, HOLLIS D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Gastrointest Ca Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers 2007 Program/Proceedings; Abstract 108.
   Google Scholar
• SHIRK AJ, KUVER R: Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigelin Papan-1 pancreatic cancer cells. BMC Gastroenterol. (2005) 5:12.
   PubMed Web of Science ®Google Scholar
• ARNOLETTI JP, BUCHSBAUM DJ, HUANG ZQ et al.: Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J. Gastrointest. Surg. (2004) 8:960-969.
   PubMed Web of Science ®Google Scholar
• BUCK E, EYZAGUIRRE A, HALEY JD et al.: Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol. Cancer Ther. (2006) 5:2051-2059.
   PubMed Web of Science ®Google Scholar
• SAFRAN H, IANNITTI D, RAMANATHAN R et al.: Herceptin and gemcitabine formetastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. (2004) 22:706-712.
   PubMed Web of Science ®Google Scholar
• WOOD ER, TRUESDALE AT, McDONALD OB et al.: A unique structure for epidermal growth factor receptor bound to GW752016 (lapatinib). Cancer Res. (2004) 64:6652-6659.
   PubMed Web of Science ®Google Scholar
• XIA W, BISI J, STRUM J et al.: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. (2006) 66:1640-1647.
   PubMed Web of Science ®Google Scholar
• KONENCY GE, PEGRAM MD, VENKATESAN N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. (2006) 66:1630-1639.
   PubMed Web of Science ®Google Scholar
• GEYER CE, FORSTER J, LINDQUIST D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. (2006) 355:2733-2743.
   PubMed Web of Science ®Google Scholar
• SPECTOR NL, XIA W, BURRIS H III et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. (2005) 23:2502-2512.
   PubMed Web of Science ®Google Scholar
• SAFRAN H, IANNITTI D, MINER T et al.: GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. J. Clin. Oncol. (2006) 24(18S Part I):Abstract 4002.
   Google Scholar
• POPLIN E, LEVY DE, BERLIN J et al.: Phase III trial of gemctabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion (FDR)) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J. Clin. Oncol. (2006) 24(18S Part I):Abstract 4004.
   Google Scholar
• VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. (2005) 23:3536-3544.
   PubMed Web of Science ®Google Scholar
• HUANG S, ARMSTRONG EA, BENAVENTE S et al.: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64:5355-5362.
   PubMed Web of Science ®Google Scholar
• PEREZ-TORRES M, GUIX M, GONZALEZ A, ARTEAGA CL: Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J. Biol. Chem. (2006)281:40183-40192.
   PubMed Web of Science ®Google Scholar
• BASELGA J, SCHOEFFSKI P, ROJO F et al.: A Phase I pharmacokinetic (PK) and molecular pharmcodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2006) 24(18S Part I):Abstract 3006.
   Web of Science ®Google Scholar
• CHUNG GG, YOON HH, ZERKOWSKI MP et al.: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer (2006) 106:1677-1684.
   PubMed Web of Science ®Google Scholar
• WEY JS, FAN F, GRAY MJ et al.: Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer (2005) 104:427-438.
   PubMed Web of Science ®Google Scholar
• YANG AD, RAMSAY CAMP E, FAN F et al.: Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. (2006) 66:46-51.
   PubMed Web of Science ®Google Scholar
• ITO D, FUJIMOTO K, MORI T et al.: In vivo antitumor effects of the mTOR inhibitor CC1-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer (2006) 118:2337-2343.
   PubMed Web of Science ®Google Scholar
• OETTLE H, POST S, NEUHAUS P et al.: Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 297:267-277.
   PubMed Web of Science ®Google Scholar